A B S T R A C T Somatostatin (SRIF) is localized in the hypothalamus, extrahypothalamic brain, and throughout the gastrointestinal tract. Release of gastrointestinal SRIF-like immunoreactivity (SRIF-LI) is under nutrient regulation but the effect of nutrients on neural SRIF-LI is unknown. The present studies examined the effects of glucose uptake and metabolism and hormones influencing glucose disposition on SRIF-LI release from medial basal hypothalamus (MBH) and cerebral cortex (Cx) incubated in Krebs-Ringer bicarbonate containing bacitracin. After a preincubation to achieve stable secretion, tissues were incubated for 20 min in 14 mM glucose (basal) and then, for 20 min in fresh medium with test materials. MBH SRIF-LI release was inversely related to medium glucose concentration with release in the absence of glucose (235±42 pg/MBH per 20 min) more than five times that in the presence of 25 mM glucose (46±4 pg/20 min). In the presence of 14 mM glucose MBH SRIF-LI release was stimulated above basal by agents interfering with glucose uptake including 3-0-methyl-D-glucose (42 mM Cx SRIF-LI release was slightly inhibited by decreases in medium glucose and unaffected by inhibition of glucose uptake or metabolism. These results provide evidence for nutrient regulation of MBH but not Cx SRIF-LI release and may explain inhibition of growth hormone seen in the rat in response to hypoglycemia.
A B S T R A C T Somatostatin (SRIF) is localized in the hypothalamus, extrahypothalamic brain, and throughout the gastrointestinal tract. Release of gastrointestinal SRIF-like immunoreactivity (SRIF-LI) is under nutrient regulation but the effect of nutrients on neural SRIF-LI is unknown. The present studies examined the effects of glucose uptake and metabolism and hormones influencing glucose disposition on SRIF-LI release from medial basal hypothalamus (MBH) and cerebral cortex (Cx) incubated in Krebs-Ringer bicarbonate containing bacitracin. After a preincubation to achieve stable secretion, tissues were incubated for 20 min in 14 mM glucose (basal) and then, for 20 min in fresh medium with test materials. MBH SRIF-LI release was inversely related to medium glucose concentration with release in the absence of glucose (235±42 pg/MBH per 20 min) more than five times that in the presence of 25 22±2 pg/20 min, P < 0.001). Inhibition of glucose metabolism by 2-deoxy-D-glucose resulted in dose-related stimulation of MBH SRIF-LI release (maximal at 28 mM; 201±28 pg/20 min vs. 32±4 pg/20 min, P < 0.001). Viability of MBH was unimpaired by incubation in the absence of glucose or following exposure to 2-deoxy-D-glucose as determined by reten-INTRODUCTION Somatostatin (SRIF),' the inhibitory hypothalamic regulator of pituitary growth hormone (1, 2) and thyrotropin (3, 4) release, is one of a group of peptides present in high concentration in the central nervous system (CNS), the pancreas, and gastrointestinal tract (5) . Although the highest concentration of CNS SRIFlike immunoreactivity (SRIF-LI) is present in the median eminence (6), reflecting its hypophysiotropic role, the total content of SRIF-LI is considerably greater in the cerebral cortex (6) . SRIF-LI is also present in D cells of the pancreatic islets (7) and throughout the gastrointestinal tract, with highest concentrations in the stomach (5, 6) . Pancreatic and gastrointestinal SRIF exert an important role in nutrient homeostasis (8) . Pancreatic SRIF inhibits the release of insulin (9) and glucagon (10) , possibly through a local or paracrine effect, thereby influencing nutrient disposition. Gastric SRIF regulates acid secretion directly (11) and through local inhibition of antral gastrin release (12) . In addition, gastrointestinal SRIF appears to have an inhibitory hormonal influence on nutrient, especially lipid, absorption (13) . The demonstration that nutrients, in turn, stimulate the release of gastrointestinal SRIF-LI (14, 15) further supports a role for SRIF in nutrient regulation. Glucose stimulates pancreatic SRIF-LI (14) while lipids, especially free fatty acids, stimulate intestinal SRIF-LI release (15) .
The role of CNS SRIF-LI in nutrient homeostasis is unknown. While hypothalamic SRIF-LI release has been demonstrated in response to a variety of stimuli including membrane depolarization (60 mM K+) (16, 17) , biogenic amines (dopamine) (17) , peptides (neurotensin) (17) , and hormones [growth hormone (18, 19) , somatomedins (20, 21) , triiodothyronine (22) potassium (419±16 vs. 576±37 pg/20 min, P < 0.001) or neurotensin (1,026±28 vs. 1,170±24 pg/20 min, P < 0.001). However, the incremental rise of hypothalamic SRIF-LI release above basal was unaffected by either stimulus. Cerebral cortical SRIF-LI release in response to both stimuli were unaffected by medium glucose concentration (Fig. 2) . (5) Effects of agents influencing cellular glucose uptake or utilization on SRIF-LI release from hypothalamus and cerebral 20 
cortex
In all experiments involving agents interfering with glucose metabolism hypothalamic and cerebral cortical incubations were performed in the presence of 14 mM glucose. (13) (a) 3-O-Methyl-D-glucose. Hypothalamic SRIF-LI release was stimulated by 3-0-methyl-D-glucose at a concentration of 42 mM as compared with basal release (70±5 vs. 42±3 pg/20 min, P < 0.05) (Fig. 3) .
(b) Phlorizin. Hypothalamic SRIF-LI release was markedly stimulated in the presence of 50 mM phlorizin as compared with basal release (351±63 vs. 29±2 pg/20 min, P < 0.001) (Fig. 3 (Fig. 4) .
To determine the effects of prior exposure to 2-deoxy-D-glucose on hypothalamic and cerebral cortical SRIF-LI release, a further series of incubations were performed. Tissues were first incubated for 20 min in medium containing 14 mM glucose alone or with 2-deoxy-D-glucose at concentrations ranging from 3 to 14 mM (period 1). They were next incubated for 20 min in medium containing 14 mM glucose (period 2). A dose-related stimulation of hypothalamic SRIF-LI release occurred in the presence of 2-deoxy-D-glucose as in the previous experiment (period 1, data not shown). The stimulatory effect persisted following the removal of medium containing 2-deoxy-D-glucose (period 2, Fig. 5 ). Cerebral cortical SRIF-LI release was unaffected by exposure to 2-deoxy-D-glucose. Tissues were next incubated for 20 min in medium containing 14 mM glucose together with 60 mM K+ (period 3). Hypothalamic SRIF-LI release was stimulated in the presence of 60 mM K+ during period 3 to a level that correlated with responses seen in presence of (period 1) and following (period 2) 2-deoxy-D-glucose.
Cerebral cortical SRIF-LI release in response to 60 mM K+ was unaffected by prior exposure to 2-deoxy-Dglucose up to 6 mM. SRIF-LI release from hypothalamus and cerebral cortex in response to 60 mM K+ was diminished following prior exposure to 14 mM 2-deoxy-D-glucose.
Effect of hormones influencing glucose disposition on SRIF-LI release from hypothalamus and cerebral cortex Insulin stimulated hypothalamic SRIF-LI release in a dose-related manner. The lowest insulin concentration resulting in significant stimulation was 0.1 gM (49±4 vs. 35±1 pg/20 min, P < 0.05). Cerebral cortical SRIF-LI release was unaffected by insulin ( Fig. 6 ; upper panel). Glucagon, in concentrations of 10 nM to 1 ,M failed to influence SRIF-LI release from either hypothalamus or cerebral cortex ( Fig. 6; lower panel) .
DISCUSSION
The present study demonstrates that glucose is an important regulator of hypothalamic SRIF-LI release. Reductions in medium glucose concentration to levels below those normally present in rat plasma (5-6 mM) resulted in increased hypothalamic SRIF-LI release, while increases in medium glucose concentration resulted in an inhibition of hypothalamic SRIF-LI re- (7) 2-deoxy-D -GLUCOSE, mM (7) (7) (7) (24) or blocked (phlorizin) (25) 
21- Our studies have demonstrated a marked CNS specificity of the effect of glucose on neural SRIF-LI; changes in the opposite direction in cerebral cortical and hypothalamic SRIF-LI release were produced by altering medium glucose concentration. Decreasing medium glucose concentration resulted in decreased cerebral cortical SRIF-LI release, a phenomenon that could represent a metabolic substrate energy-dependent process. A similar phenomenon may have occurred with hypothalamic SRIF-LI release that was masked by the area specific stimulatory effect of low medium glucose.
While the present studies provide the first evidence for nutrient regulation of hypothalamic SRIF-LI release, such regulation of gastrointestinal and pancreatic SRIF-LI has been well described. These observations raise the possibility of an integrated role for hypothalamic, gastrointestinal, and pancreatic SRIF in nutrient homeostasis. Evidence for such a role first appeared with the description of the inhibitory effects of exogenous SRIF on intestinal motility (28), gastric acid secretion (29) , pancreatic exocrine secretion (30) , and splanchnic blood flow (31) . These effects result in delayed or decreased nutrient absorption (13) and complement the inhibitory action of SRIF on hormones important in nutrient absorption (cholecystokinin) (32) or disposition (insulin and glucagon) (33) . In subsequent reports nutrients, most notably fatty acids (15) , were shown to stimulate gastrointestinal and pancreatic SRIF-LI release, while glucose and amino acids stimulated predominantly pancreatic SRIF-LI release (14) . Further support for a physiologic role of SRIF in fatty acid absorption was provided by experiments where passive immunization with anti-SRIF serum resulted in increased fatty acid absorption, suggesting that endogenous SRIF inhibits lipid absorption (34) . Similar experiments have suggested that SRIF also acts physiologically to inhibit hormones important in nutrient homeostasis including gastrin (12) , insulin (9) , and glucagon (10) .
While the present studies have documented an effect of ambient glucose concentration on hypothalamic SRIF-LI release, we have previously demonstrated that lesions of the ventromedial hypothalamus result in increased pancreatic SRIF-LI content and release indicating hypothalamic regulation of pancreatic SRIF (35) . It thus appears that peripheral nutrient homeostasis can influence hypothalamic SRIF-LI whereas hypothalamic centers influence pancreatic hormone secretion and thus, in turn, nutrient disposition.
The effect of insulin and glucagon on CNS SRIF-LI release was determined to assess the effect of hormones influencing glucose disposition. Insulin resulted in a dose-related stimulation of hypothalamic SRIF-LI release that was apparent only at concentrations of 0.1 ,gM and greater. We have previously reported that insulin at physiologic concentrations (4 nM) has no effect on hypothalamic SRIF-LI release (21) . The high levels of insulin required to achieve stimulation of SRIF-LI release could possibly be explained by binding of insulin to a somatomedin-C receptor, an effect previously described in other tissues (36) . We have previously demonstrated that somatomedin-C stimulates SRIF-LI release at physiologic concentrations (5-50 ng/ml) (21) . The lack of stimulation of cerebral cortical SRIF-LI release by the same insulin concentrations provides further documentation of area specificity of the response.
In summary we have documented an inverse doserelated effect of glucose on hypothalamic but not cerebral cortical SRIF-LI release. The effect required the entry of glucose into cells and its subsequent metabolism. Insulin had no effect on hypothalamic SRIF-LI release at physiologic concentrations but exhibited a stimulatory effect at high concentrations. This effect is not mediated by glucose entry into cells (which decreases SRIF-LI release) but may result from binding of insulin to a hypothalamic somatomedin-C receptor. These data provide an explanation for the observation of a decrease in serum growth hormone levels in rats during insulin-induced hypoglycemia (37) . In man, however, the same stimulus results in growth hormone stimulation suggesting either that SRIF has a more prominent role in growth hormone regulation in the rat or that regulation of hypothalamic SRIF release differs in the two species.
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